Zydus receives final approval from the USFDA for Acyclovir Cream

Zydus receives final approval from the USFDA for Acyclovir Cream

The product will be launched shortly in the US market. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India

FPJ Web DeskUpdated: Thursday, March 02, 2023, 03:55 PM IST
article-image
Zydus receives final approval from the USFDA for Acyclovir Cream | Image: Zydus Lifesciences (Representative)

Zydus Lifesciences Limited announced that the company has received final approval from the United States Food and Drug Administration (USFDA) for Acyclovir Cream, via an exchange filing.

Acyclovir belongs to a class of medications known as antivirals. Acyclovir cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips.

The product will be launched shortly in the US market. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India.

Acyclovir Cream, 5% had annual sales of USD 16.9 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 348 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

Why India-US Trade Deal Failed, The Story Behind 25% Tariffs & Broken Talks

Why India-US Trade Deal Failed, The Story Behind 25% Tariffs & Broken Talks

Morgan Stanley Expects Possible RBI Rate Cut In October Amid Tariff Concerns, Steady GDP Outlook

Morgan Stanley Expects Possible RBI Rate Cut In October Amid Tariff Concerns, Steady GDP Outlook

Infosys Launches Advanced AI, Cybersecurity & Space Tech Center In India

Infosys Launches Advanced AI, Cybersecurity & Space Tech Center In India

Stock Market Ends Slightly Lower, Investors React To RBI's Unchanged Repo Rate

Stock Market Ends Slightly Lower, Investors React To RBI's Unchanged Repo Rate

PFC Q1 Net Profit Jumps 25% To ₹8,981 Crore on Higher Interest Income; Gross NPA Falls To 1.47%

PFC Q1 Net Profit Jumps 25% To ₹8,981 Crore on Higher Interest Income; Gross NPA Falls To 1.47%